How has the increasing focus on biopharmaceuticals affected your business?
In the sense that biopharmaceuticals are now a growth industry as opposed to the traditional chemical–pharmaceutical industry,
it has impacted us greatly. Single-use process components are ideal for the biopharmaceutical arena. Batches are typically
smaller and most of the processes are not using chemicals that will affect the components we provide.
How will the industry remain innovative as it reduces spending on research?
We have not seen any decline in innovations; however, it is now coming from other sources. What we are seeing is the partnership
and licensing of a molecule to a start-up or small biotechnology company. This model allows the big companies to reduce their
R&D budgets and risk exposure while allowing the smaller companies to get funding through private equity or other sources.
If the product is a success, the investors win as well as the large biotechnology companies that will purchase the smaller
company in the end.
Do you see a new industry trend emerging?
Regulatory compliance has become a big part of our customers' requirements. Biotechnology companies are demanding much tighter
control and assurance of our products. As a supplier of single-use components and systems, SaniSure is now being asked to
have control of our supplier base and the raw materials they are using. The onus is on us to assure a consistent and stable
level of quality and control.